How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2020 financial year.
ESE is funded through a number of industry and non-industry sources;
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- The list of all industry and non-industry revenue sources in 2020 are listed below:
- Advanced Accelerator Applications
- Akcea Theraputics
- Alexion
- Amryt Pharmaceuticals DAC
- Ascendis Pharma
- Brahms GMBH
- Chiasma
- Clinical Endocrinology Trust
- Crinetics Pharmaceuticals
- Diurnal
- Gilead Sciences Europe
- Health Unlimited
- HRA Pharma
- International Medical Press
- Ipsen
- ITM Isotopen Technologien Munchen AG
- Kyowa Kirin International Plc
- Liberum
- Novo Nordisk
- Pfizer
- Recordati
- Sandoz
- Siemens
- Strongbridge
- Takeda/Shire
- Thyroid Federation
- Unipharma
- Of the revenue into ESE in the 2020 accounts 62.3% was provided by industry.
- The highest contribution from a single company represented 15.9% of the industry revenue and 9.9% of ESE revenue overall.